KR20160075794A - 질환 및 질병 치료용 칼시토닌 모방체 - Google Patents

질환 및 질병 치료용 칼시토닌 모방체 Download PDF

Info

Publication number
KR20160075794A
KR20160075794A KR1020167015410A KR20167015410A KR20160075794A KR 20160075794 A KR20160075794 A KR 20160075794A KR 1020167015410 A KR1020167015410 A KR 1020167015410A KR 20167015410 A KR20167015410 A KR 20167015410A KR 20160075794 A KR20160075794 A KR 20160075794A
Authority
KR
South Korea
Prior art keywords
seq
leu
thr
calcitonin
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020167015410A
Other languages
English (en)
Korean (ko)
Inventor
모르텐 카르스달
김 헨릭센
김 피츠 안드레아센
Original Assignee
키바이오사이언스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201320112A external-priority patent/GB201320112D0/en
Priority claimed from GB201414706A external-priority patent/GB201414706D0/en
Application filed by 키바이오사이언스 아게 filed Critical 키바이오사이언스 아게
Publication of KR20160075794A publication Critical patent/KR20160075794A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020167015410A 2013-11-14 2014-11-10 질환 및 질병 치료용 칼시토닌 모방체 Abandoned KR20160075794A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201320112A GB201320112D0 (en) 2013-11-14 2013-11-14 Calcitonin Mimetics for treating diseases and disorders
GB1320112.4 2013-11-14
GB201414706A GB201414706D0 (en) 2014-08-19 2014-08-19 Calcitonin mimetics for treating diseases and disorders
GB1414706.0 2014-08-19
PCT/EP2014/074207 WO2015071229A1 (en) 2013-11-14 2014-11-10 Calcitonin mimetics for treating diseases and disorders

Publications (1)

Publication Number Publication Date
KR20160075794A true KR20160075794A (ko) 2016-06-29

Family

ID=51947308

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167015410A Abandoned KR20160075794A (ko) 2013-11-14 2014-11-10 질환 및 질병 치료용 칼시토닌 모방체

Country Status (24)

Country Link
US (2) US10232021B2 (enExample)
EP (3) EP3470422A1 (enExample)
JP (1) JP6639389B2 (enExample)
KR (1) KR20160075794A (enExample)
CN (1) CN105722854B (enExample)
AU (2) AU2014350328B2 (enExample)
BR (1) BR112016010643A2 (enExample)
CA (1) CA2928654A1 (enExample)
CY (2) CY1119976T1 (enExample)
DK (2) DK3321278T3 (enExample)
ES (2) ES2713851T3 (enExample)
HR (2) HRP20180337T1 (enExample)
HU (2) HUE037663T2 (enExample)
LT (2) LT3321278T (enExample)
MX (1) MX373251B (enExample)
NO (1) NO3068796T3 (enExample)
PH (1) PH12016500705A1 (enExample)
PL (2) PL3068796T3 (enExample)
PT (2) PT3321278T (enExample)
RS (2) RS57152B1 (enExample)
RU (1) RU2689551C1 (enExample)
SI (2) SI3321278T1 (enExample)
TR (1) TR201802765T4 (enExample)
WO (1) WO2015071229A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201500263D0 (en) * 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
KR101869595B1 (ko) 2016-06-08 2018-06-21 부경대학교 산학협력단 성게 유래 칼시토닌 유사 펩타이드를 유효성분으로 포함하는 골 질환 예방 또는 치료용 조성물
CN108424460A (zh) * 2017-02-13 2018-08-21 成都贝爱特生物科技有限公司 GLP-1类似物和davalintide类似物的融合蛋白制备及其用途
CN106880835A (zh) * 2017-02-17 2017-06-23 云南同方科技有限公司 用于缓解高血压症状的植物精油复合物制备及应用
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
GB201813678D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
EP4058047A1 (en) 2019-11-11 2022-09-21 Boehringer Ingelheim International GmbH Npy2 receptor agonists
KR20230045088A (ko) 2020-08-07 2023-04-04 베링거 인겔하임 인터내셔날 게엠베하 가용성 npy2 수용체 작용제
TWI901926B (zh) 2020-12-18 2025-10-21 美商美國禮來大藥廠 雙重澱粉素及降鈣素受體促效劑及其用途
CN120112280A (zh) 2022-08-29 2025-06-06 伊莱利利公司 用于口服递送的组合物
WO2025240893A1 (en) 2024-05-17 2025-11-20 Eli Lilly And Company 4-phenyl-1h-pyrazolo[3,4-b]pyridine-5-carboxamide derivatives as amylin and/or calcitonin receptor agonists for the treatment of type 2 diabetes, obesity or overweight

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
JPH03240797A (ja) * 1990-02-15 1991-10-28 Sagami Chem Res Center 新規カルシトニン誘導体
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
JPH04149198A (ja) * 1990-10-12 1992-05-22 Sagami Chem Res Center カルシトニン誘導体
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DK1005526T3 (da) 1997-04-16 2011-02-07 Unigene Lab Inc Direkte ekspression af peptider i kulturmedium
DE19736457C2 (de) * 1997-08-21 2001-08-23 Fraunhofer Ges Forschung Calcitonin-Derivate mit einer Verbrückung zwischen den Aminosäuren an den Positionen 17 und 21
WO2000033866A1 (en) 1998-12-04 2000-06-15 Provalis Uk Limited Pharmaceutical compositions containing insulin
AU4216700A (en) 1999-04-05 2000-10-23 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
IE20040202A1 (en) 2003-03-28 2004-10-06 Sigmoid Biotechnologies Ltd Solid oral dosage form containing seamless microcapsules
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
EP2316473B1 (en) 2003-07-23 2013-08-21 Novartis AG Use of calcitonin in osteoarthritis
WO2005094785A2 (en) 2003-09-17 2005-10-13 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
JP2008506750A (ja) 2004-07-22 2008-03-06 ティオマトリックス・フォルシュンクス・ウント・べラートゥンクス・ゲーエムベーハー チオール基を含む化合物の排出ポンプ抑制剤としての使用
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
US8815583B2 (en) 2005-06-24 2014-08-26 Enteris Biopharma, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
JP5222727B2 (ja) 2005-09-06 2013-06-26 オーラメッド・ファーマスーティカルズ・インコーポレイテッド タンパク質を経口投与するための方法及び組成物
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
EP1834635B1 (en) 2006-03-13 2011-07-06 Advanced in Vitro Cell Technologies, S.L. Stable nanocapsule systems for the administration of active molecules
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
EP3515022B1 (en) * 2011-10-25 2022-08-17 Nicira Inc. Chassis controllers for converting universal flows
CN103998052B (zh) * 2011-11-02 2016-08-17 关键生物科学有限公司 用于治疗疾病和紊乱的肽类似物

Also Published As

Publication number Publication date
EP3321278B1 (en) 2019-01-09
SI3321278T1 (sl) 2019-04-30
TR201802765T4 (tr) 2018-03-21
DK3068796T3 (en) 2018-03-05
HUE037663T2 (hu) 2018-09-28
RU2689551C1 (ru) 2019-05-28
JP2016538282A (ja) 2016-12-08
EP3470422A1 (en) 2019-04-17
PL3068796T3 (pl) 2018-07-31
EP3321278A1 (en) 2018-05-16
ES2713851T3 (es) 2019-05-24
PT3321278T (pt) 2019-03-19
CN105722854A (zh) 2016-06-29
MX2016006049A (es) 2016-08-12
EP3068796B1 (en) 2018-01-31
US10232021B2 (en) 2019-03-19
PH12016500705B1 (en) 2016-05-30
RS57152B1 (sr) 2018-07-31
EP3068796A1 (en) 2016-09-21
HUE044465T2 (hu) 2019-10-28
AU2018202480A1 (en) 2018-04-26
WO2015071229A1 (en) 2015-05-21
HRP20180337T1 (hr) 2018-05-18
JP6639389B2 (ja) 2020-02-05
RS58530B1 (sr) 2019-04-30
SI3068796T1 (en) 2018-05-31
NO3068796T3 (enExample) 2018-06-30
CA2928654A1 (en) 2015-05-21
LT3321278T (lt) 2019-03-12
PL3321278T3 (pl) 2019-06-28
ES2660788T3 (es) 2018-03-26
US20170143800A1 (en) 2017-05-25
AU2014350328A1 (en) 2016-05-19
BR112016010643A2 (pt) 2017-12-05
PH12016500705A1 (en) 2016-05-30
LT3068796T (lt) 2018-05-10
HRP20190356T1 (hr) 2019-04-19
DK3321278T3 (en) 2019-03-25
RU2016123180A (ru) 2017-12-19
CY1119976T1 (el) 2018-12-12
US20190142903A1 (en) 2019-05-16
MX373251B (es) 2020-05-04
PT3068796T (pt) 2018-03-02
CN105722854B (zh) 2020-08-04
AU2014350328B2 (en) 2018-04-05
CY1121332T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
JP6639389B2 (ja) 疾患および障害を処置するためのカルシトニン模倣体
KR102019911B1 (ko) 질병 및 장애 치료용 펩타이드 유사체
AU2025205152A1 (en) Acylated calcitonin mimetics
KR20170120576A (ko) 질환 및 질병 치료용 칼시토닌 유사체
WO2018211111A1 (en) Dual amylin and calcitonin receptor agonists for treating diseases and disorders
KR20190131054A (ko) 질환 및 장애를 치료하기 위한 칼시토닌 모방체
HK40007644A (en) Calcitonin mimetics for treating diseases and disorders
HK1247623B (en) Calcitonin mimetics for treating diseases and disorders
HK1247623A1 (en) Calcitonin mimetics for treating diseases and disorders
WO2020039052A1 (en) Calcitonin mimetics for treating diseases and disorders
HK1227415A1 (en) Calcitonin mimetics for treating diseases and disorders
HK1227415B (en) Calcitonin mimetics for treating diseases and disorders

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000